Solutions available for licensing

Explore some of our licensing opportunities

• ADMiER

  ADMiER reduces the time required to diagnose dry eye disease from an estimated 18 minutes of chair-time to just three minutes. Help us enhance clinical outcomes for patients with more accurate disease characterisation through licensing. 

• Bio-Dash

  Accelerate the development of this practically-focused wellbeing program through licensing or direct investment. Bio-Dash is a practical and engaging wellbeing program that equips individuals to self-manage their mental health using evidence-based strategies and personal feedback. 

• Broad and ultra-potent anti-HIV-1 antibodies 

  Accelerate the development of broad and ultra-potent anti-HIV-1 antibodies through licensing or direct investment.

• COVID-19 vaccine platform 

  A COVID-19 vaccine platform that enables rapid production of second-generation vaccines against SARS-CoV-2 variants of concern has been developed by University of Melbourne researchers.

• Foundations of Wellbeing

  Accelerate the development of this online wellbeing program for the workplace  through licensing or direct investment. This evidence-based online wellbeing program is designed to improve employee engagement, enjoyment and productivity at work.   

• Left Write Hook

  Left Write Hook equips adult survivors of sexual violence to actively take back power through an evidence-based program blending creative writing and boxing.  Accelerate the development of this recovery empowerment program for sexual abuse survivors through licensing or direct investment.

• Monoclonal antibodies against COVID-19

  New SARS-CoV-2 variants have rendered ineffective most US Food and Drug Administration-approved COVID-19 antibody treatments and reduced vaccine efficacy.

• New therapeutics for autoimmune diseases

  Help to accelerate the development of small molecule therapeutics against lupus erythematosus through licensing or direct investment.

• Non-invasive biomarker for diabetic neuropathy 

  A biomarker produced in tears could be used in early diagnosis and monitoring of neuropathy in people with diabetes, in place of current invasive or difficult-to-access diagnostic methods.

• Tissue-engineered corneal endothelium graft 

  Partner with us to license graft technology that treats corneal dysfunction. 

• Ultra-thin single crystal diamond membrane

  Partner with us to accelerate the development and validation of the fabrication method for single crystal diamond membranes, through licensing and/or co-development.